Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins

International Journal of Biomedical Science

Volumn 5, Issue 4, 2009, Pages 402-410

  De Juan Franco, Elena ^a   Pérez, Antonio ^a,b   Ribas, Vicent ^a   Sánchez Hernández, Juan Antonio ^b   Blanco Vaca, Francisco ^a,b   Ordóñez Llanos, Jordi ^a,b   Sánchez Quesada, José Luis ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

HDL; HDL antioxidant capacity; LDL; Lipoproteins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGAROSE; ALKADIENE; ARYLDIALKYLPHOSPHATASE; COPPER SULFATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYCLOADDITION; ELECTROPHORESIS; ENZYME ACTIVITY; FEMALE; GEL; GEL FILTRATION CHROMATOGRAPHY; HUMAN; INHIBITION KINETICS; MALE; OXIDATION KINETICS; PROTEIN ANALYSIS; PROTEIN ISOLATION; STANDARDIZATION;

EID: 77953429843     PISSN: 15509702     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol. 1996;16:831.
2. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062.
3. Parthasarathy S, Litvinov D, Selvarajan K, Garelnabi M. Lipid peroxidation and decomposition - conflicting roles in plaque vulnerability and stability. Biochim Biophys Acta. 2008;1781:221.
4. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199.
5. Navab M, Yu R, Gharavi N, et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007;9:244.
6. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764.
7. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol. 2004;15:399.
8. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57.
9. Kunitake ST, Jarvis MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A. 1992;89:6993.
10. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol. 1999;19:2226.
11. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:786.
12. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23:1881.
13. Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:e149.
14. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345.
15. Radding CM, Steinberg D. Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. J Clin Invest. 1960;39:1560.
16. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67.
17. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem. 1989;180:242.
18. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38:153.
19. Benítez S, Sánchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 2003;108:92.
20. Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986;128:181.
21. McPherson PA, Young IS, McKibben B, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res. 2007;48:86.
22. Nobécourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005;48:529.
23. Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem. 2006;39:19.
24. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res. 1992;33:1551.
25. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipemia, inflammation and atherosclerosis. Pharmacol Rev. 2006;58:342.
26. Tribble DL. Lipoprotein oxidation in dyslipemia: insights into general mechanisms affecting lipoprotein oxidative behaviour. Curr Opin Lipidol. 1995;6:196.
27. Hasselwander O, McEneny J, McMaster D, et al. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis. 1999;143:125.
28. Graham A, Hassall DG, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:193.
29. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419.
30. Watson AD, Navab M, Hama SY, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774.